Abstract: Autoimmune blistering diseases (AIBD) are a group of autoimmune antibody-mediated blistering disorders affecting the skin and mucous membranes. Traditional treatments mainly rely on glucocorticoids and immunosuppressants. In recent years, JAK inhibitors have emerged as a promising research direction due to their properties of targeting and regulating the JAK-STAT signaling pathway, as well as blocking inflammatory and immune responses. The role of the JAK-STAT pathway in the pathogenesis of AIBD are reviewed in this paper, with a focus on the clinical applications of JAK inhibitors such as ruxolitinib, tofacitinib, and upadacitinib in the treatment of pemphigus and pemphigoid.

Key words: Janus kinase inhibitor, autoimmune bullous diseases, pemphigus, pemphigoid, JAK-STAT signaling pathway